Iovance Biotherapeutics Inc. Common Stock vs Range Nuclear Renaissance ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while Range Nuclear Renaissance ETF trades at $61.06 (market cap $698.21M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 8.7× Range Nuclear Renaissance ETF's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Range Nuclear Renaissance ETF for 18 Days on average.
| IOVA | NUKZ | |
|---|---|---|
Market Cap | $6.04B | $698.21M |
Volume | 14,805,993 | 57,444 |
Sector | Health | Sector/Thematic |
52-Week High | $14.82 | $76.23 |
52-Week Low | $1.81 | $60.23 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $5.97B | — |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →